GET DAILY SIGNALSOPKO Health (OPK) Narrows Q3 Loss to $0.05 Per Share While Advancing Its Biopharma Focus
Key Takeaways
- OPKO Health reported a third-quarter 2026 GAAP loss of $0.05 per share, narrower than the consensus estimate of a $0.07 loss.
- Continuing operations revenue grew 16% year over year to $65.4 million, driven by higher Lilly royalties, Rayaldee sales, and international growth.
- BioReference Health is now classified as discontinued operations following the announced $722 million asset sale to Labcorp.
- The Global Products segment swung to $6.0 million in operating income, versus a $1.2 million operating loss a year earlier.
- Cash, cash equivalents and restricted cash ended the quarter at $403.2 million, supported by a $125 million royalty financing.
- OPKO repurchased 7.05 million shares for approximately $10.6 million during the quarter.
Earnings Context and Why It Matters
OPKO Health is in the middle of a deliberate strategic transformation. With the announced sale of select BioReference Health assets to Labcorp for approximately $722 million in cash, the company is exiting the clinical laboratory business to become a focused biopharmaceutical company built around its Global Products segment and an Innovative Biotech pipeline. This report is the first in which BioReference is presented as discontinued operations, meaning investors must reassess the company's true revenue base and profitability profile. The results also signal whether OPKO's remaining businesses, particularly Rayaldee and royalty streams from partners such as Lilly and Pfizer, can fund the company's expanding research and development efforts without additional dilution. I also checked this using Tickeron’s AI Screener to see how OPK compares to others in the industry.
Reported Results
For the third quarter of 2026, OPKO Health reported a GAAP net loss of $0.05 per share, beating the consensus estimate of a $0.07 loss. Consolidated continuing operations revenue rose 16% to $65.4 million from $56.4 million in the prior-year quarter, while the operating loss narrowed to $31.4 million from $33.6 million.
Revenue reflects only the businesses OPKO will retain after closing the Labcorp transaction. The Global Products segment grew to $48.4 million from $39.4 million, with Rayaldee revenue climbing to $8.6 million from $7.5 million and licensing, collaboration and other revenue rising to $6.6 million from $1.8 million, including $5.8 million in royalties from Lilly. The segment posted $6.0 million in operating income versus a $1.2 million loss a year ago. The Innovative Biotech segment generated $17.0 million in revenue, flat year over year, while its operating loss widened to $26.8 million from $22.5 million as research and development investment increased. Discontinued operations, reflecting BioReference, generated $71.8 million in revenue, down from $95.2 million a year earlier.
Market Reaction and Investor Sentiment
Investor attention around this earnings event centered less on the headline numbers and more on the strategic repositioning of the company. Because BioReference was reclassified into discontinued operations, the reported revenue base is now smaller, which can make direct year-over-year and consensus comparisons less intuitive. The narrower-than-expected loss and the swing to profitability in Global Products were viewed as encouraging, while the widening operating loss in Innovative Biotech underscores the rising cost of advancing the ModeX pipeline. Sentiment is likely to remain tied to the completion of the Labcorp transaction and the pace of clinical milestones rather than near-term bottom-line results.
Forward Outlook and Key Factors to Monitor
The most significant item on the horizon is the closing of the Labcorp transaction, which is subject to regulatory approvals and customary conditions. The deal includes roughly $722 million in cash consideration at closing, plus up to $150 million in additional payments over up to ten years tied to 4Kscore sales. This capital is expected to fund OPKO's pipeline and potentially accelerate shareholder returns.
Investors should also watch the clinical development calendar. ModeX continues to advance several programs, including MDX2001 and MDX2003, its tetraspecific T-cell engagers, with subcutaneous dosing cohorts expected in late 2026 or 2027. The company's first in vivo CAR T program, MDX3001, is targeting first-in-human studies in mid-2027, initially in autoimmune disease.
On the commercial side, Rayaldee and international pharmaceutical operations provide recurring revenue, while royalty streams from NGENLA and Lilly's mazdutide offer non-dilutive cash flow. Key risks include the pace of research and development spending, execution of the Labcorp transition, and the outcome of ongoing litigation, including the Israeli tax assessment. Balanced against these factors is a strengthened balance sheet, with $403.2 million in cash and restricted cash at quarter-end and an active share repurchase program with approximately $84.3 million remaining under its authorization.
Exploring Tickeron’s AI Tools for Biotech Analysis
In my own research process, I turned to Tickeron’s AI Screener to quickly filter comparable names in the biotech space and review technical and fundamental signals alongside OPK. The tool makes it straightforward to scan for similar opportunities and monitor how peers are reacting to sector developments, which helped put these results in broader context without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OPK in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026
The 10-day moving average for OPK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on OPK as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for OPK just turned positive on October 19, 2026. Looking at past instances where OPK's MACD turned positive, the stock continued to rise in 28 of 40 cases over the following month. The odds of a continued upward trend are 70%.
OPK moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPK advanced for three days, in 159 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 90 of 141 cases where OPK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
OPK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.116) is normal, around the industry mean (66.911). P/E Ratio (-25.286) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.134) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OPK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry MedicalSpecialties
Advertisement